Company / SG&A Expense
MADRIGAL PHARMACEUTICALS, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$813.8M
FY2025
5-year range
$37.3M / $813.8M
FY2021-FY2025
Trend
+87.1%
vs FY2024
Sector context
#25 of 213
Health Care
What the data says
MADRIGAL PHARMACEUTICALS, INC.'s sg&a expense of $814M is higher than 88% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 5 consecutive years, from $22M in FY2020 to $814M in FY2025.
Based on SEC 10-K filings.
$814M in FY2025 with a 5-year CAGR of +106.1%. Top quartile in the Health Care sector.
Increased from $108M to $814M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +156.7%
- 5-Year CAGR
- +106.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 213This company $813.8M Sector average $722.3M
▼
+12.7% above sector average
Key checks
Key Insights
- MADRIGAL PHARMACEUTICALS, INC.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +106.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 87.1% year-over-year.
- Ranks #25 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $813.8M | +87.1% |
| FY2024 | $435.1M | +302.3% |
| FY2023 | $108.1M | +124.7% |
| FY2022 | $48.1M | +29.0% |
| FY2021 | $37.3M | +70.7% |
| FY2020 | $21.9M | -3.5% |
| FY2019 | $22.6M | +48.1% |
| FY2018 | $15.3M | +99.3% |
| FY2017 | $7.7M | -17.4% |
| FY2016 | $9.3M | -41.0% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026